A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors
Authors:
Abstract
No abstract availableKeywords
Funding Information
- Dana-Farber Cancer Institute
- Novartis Pharmaceuticals Corporation
- National Institutes of Health (R01CA238039)
This publication has 89 references indexed in Scilit:
- Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional ImplicationsScandinavian Journal of Immunology, 2013
- A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCsScientific Reports, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Inhibition of Matrix Metalloproteinase 14 (MMP-14)-mediated Cancer Cell MigrationJournal of Biological Chemistry, 2011
- An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cellsNature Communications, 2011
- Regulation of human NK-cell cytokine and chemokine production by target cell recognitionBlood, 2010
- ADAM-17: the enzyme that does it allCritical Reviews in Biochemistry and Molecular Biology, 2010
- An six-amino acid motif in the α3 domain of MICA is the cancer therapeutic target to inhibit sheddingBiochemical and Biophysical Research Communications, 2009
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicityProceedings of the National Academy of Sciences, 2006